LONDON (Alliance News) - Oncimmune Holdings PLC and Genostics Co Ltd on Friday said a multi-centre case control study on early lung cancer detection in China has started.
The immunodiagnostics company said the study is using an extended panel of autoantibodies to accommodate variations in the biomarkers expressed on cancer cells in Asian populations.
Oncimmune will study 1,000 early lung cancers at five leading academic health centres across China. The results are expected in the fourth quarter of 2019 and will be used to support Oncimmune's application for approval of EarlyCDT-Lung with the China Food & Drug Administration.
"This study is part of our ongoing programme to support the introduction of EarlyCDT-Lung in China, which is progressing to schedule," said Oncimmune Chief Executive Adam Hill.
"This China-wide validation study in the Chinese population will help with EarlyCDT-Lung's future effective commercialisation and accelerate the introduction of an early lung cancer screening program in China, benefiting Chinese patients and families," added Gene Group Holdings Ltd Chair Cheung To.
Genostics is a subsidiary of Gene Group.
Oncimmune shares were trading 3.9% higher on Friday at 92.50 pence each.
Oncimmune (ONC)